

Advance your Immuno-Oncology Innovation Project with up to 400.000 NOK

Deadline to apply: November 15, 2014

The opportunity

Thanks to Innovation Norway Oslo Cancer Cluster can advance novel projects within Immuno-Oncology with a total of MNOK 1, 2. The funding shall **mobilize projects, help start-ups to achieve critical milestones or initiate novel, collaborative projects in existing biotech companies**. The funding shall put the projects in a position to receive funding from private investors or the ordinary funding schemes of Innovation Norway or other soft funding agencies.

Who can apply?

All Oslo Cancer Cluster members can apply, but a Norwegian SME must be the principal applicant. Another prerequisite for funding is that at least two partners participate in the project. This can be another SME, a large enterprise or a public body like a hospital.

What kind of projects qualify?

Projects within immuno-oncology aiming to develop new therapeutics, diagnostics, advanced technology platforms including projects that combine existing technologies for novel and different applications.

The funding supports achieving relevant milestones such as:

- Verification of concept / preclinical proof-of-concept
- Move the project into clinical development
- Achieve initial clinical proof-of-concept
- Strengthen an existing pipeline with a new project
- Define new application areas for existing technology platforms

Results should be achieved within a year after project start.

How much funding can you apply for?

Depending on the quality of the applications received, 2 – 3 projects get funding. The maximum amount that can be granted is MNOK 0, 4, while minimum funding is MNOK 0, 3. The grant can fund up to 50 % of the payable cost in the project.

How and when to apply?

Please fill in the application form attached. The deadline for submission: November 15th, 2014 by e-mail to jh@oslocancercluster.no. Questions regarding the application may be directed to Jutta Heix at +47 941 63 089 or Ole Johan Borge, Innovation Norway at +47 975 00 583 or olbor@innovasjon Norge.no

How are the applications evaluated?

A selection committee with representatives from Oslo Cancer Cluster's Board, Innovation Norway with academic and clinical experts as advisors will review the applications. Projects are selected based on their novelty, commercial potential and feasibility.

Important: the funding must make a significant difference for the applicant. This can be in the sense that the project will not be materialized without the funding or that the project will be better (e.g. broader in scope or deeper in its investigation).

Why should you participate?

If you aim to advance your immuno-oncology innovation project towards commercial development, this funding can help you to achieve your next important milestone faster and to qualify for other funding schemes.

Additional benefit: All applications are reviewed by Innovation Norway to see if they qualify for other funding schemes. What we are working for is further developing Immuno-Oncology strength in our cluster with new exciting projects!